Kaushik Ghoshal - 12 Aug 2024 Form 4 Insider Report for RESMED INC (RMD)

Signature
Kaushik Ghoshal, President SaaS Business
Issuer symbol
RMD
Transactions as of
12 Aug 2024
Net transactions value
-$1,201,944
Form type
4
Filing time
13 Aug 2024, 15:51:40 UTC
Previous filing
23 May 2024
Next filing
16 Aug 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMD ResMed Common Stock Options Exercise $199,839 +2,086 +16% $95.80 15,118 12 Aug 2024 Direct F1
transaction RMD ResMed Common Stock Options Exercise $658,817 +6,877 +45% $95.80 21,995 12 Aug 2024 Direct F1
transaction RMD ResMed Common Stock Options Exercise $105,401 +1,037 +4.7% $101.64 23,032 12 Aug 2024 Direct F1
transaction RMD ResMed Common Stock Sale $2,166,000 -10,000 -43% $216.60 13,032 12 Aug 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -2,086 -100% $0.000000* 0 12 Aug 2024 ResMed Common Stock 2,086 $95.80 Direct F1, F2
transaction RMD ResMed Common Stock Options Options Exercise $0 -6,877 -100% $0.000000* 0 12 Aug 2024 ResMed Common Stock 6,877 $95.80 Direct F1
transaction RMD ResMed Common Stock Options Options Exercise $0 -1,037 -10% $0.000000 9,260 12 Aug 2024 ResMed Common Stock 1,037 $101.64 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction was conducted under a Rule 10b5-1 plan adopted April 29, 2024.
F2 Represents date options first became exercisable. Options vest 1/3 per year.